Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Archivos De Bronconeumologia|July 30, 2024
Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility AssessmentDaniel Orive, Mirari Echepare, Franco Bernasconi-Bisio, et al.
Molecular Cancer|April 20, 2024
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulationAnder Puyalto, María Rodríguez-Remírez, Inés López, et al.
Cell Reports|March 13, 2026
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancerAndrea Pasquier, Cristina Viu-Idocin, Andrea Arricibita, et al.
The Journal of Experimental Medicine|September 28, 2022
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicityKarmele Valencia, Mirari Echepare, Álvaro Teijeira, et al.
American Journal of Respiratory and Critical Care Medicine|March 31, 2012
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinomaIker Antón, Eva Molina, Diego Luis-Ravelo, et al.
Cancer Research|September 21, 2022
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy EfficacyAlvaro Teijeira, Saray Garasa, Carlos Luri-Rey, et al.
Disease Models & Mechanisms|December 6, 2021
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinomaKarmele Valencia, Cristina Sainz, Cristina Bértolo, et al.
Scientific Reports|October 30, 2019
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1Maria Villalba, Esther Redin, Francisco Exposito, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2022
YES1 Is a Druggable Oncogenic Target in SCLCEsther Redin, Eva M Garrido-Martin, Karmele Valencia, et al.
Molecular Therapy. Nucleic Acids|August 31, 2023
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonistsAssunta Cirella, Elixabet Bolaños, Carlos Luri-Rey, et al.
Pageof 5